Multi-drug resistant tuberculosis, or MDR-TB, is a form of tuberculosis resistant to at least two most effective antituberculosis drugs. These are isoniazid and rifampin. It means that these antibiotics will not be effective in killing the bacteria.
According to WHO, due to timely diagnostics of MDR-TB cases using modern diagnostics techniques, the number of MDR-TB cases increased from 3,482 in 2009 to 8,430 in 2014.
Expenditures for implementation of the Nation-Wide Social Targeted Program to Fight Tuberculosis amounted to UAH 346,174 thousand in 2014, among them UAH 188,507 from the State Budget of Ukraine, and UAH 157,667 from the Global Fund.
Antituberculosis drugs at the cost of the State Budget of Ukraine were procured for UAH 152.9 million, which amounts to 90% of the total expenditures for antituberculosis drug procurement for 2014, which allowed for provision of continuous treatment to all patients with sensitive TB and 50% of patients with MDR-TB. Other 50% of 2nd-line drugs for MDR-TB treatment were received by Ukraine as humanitarian assistance at the cost of the Global Fund.
Overall, there are over 15 thousand patients with the 4th category (40.3%) registered at tuberculosis facilities in Ukraine. Approximately 90% of MDR-TB cases detected over this period started their treatment with 2nd-line antituberculosis drugs within the last five years (except 2010), however, the absolute number of MDR-TB cases increased from 3,186 in 2009 to 8,430 in 2013. The introduction of a large-scale program of treatment of MDR-TB patients should become a leading factor in decreasing the scales of TB epidemics in the country.
The following number of patients with multi-drug resistant tuberculosis enrolled for the treatment within the framework of the grant of the Global Fund to Fight AIDS, Tuberculosis and Malaria in the area “Tuberculosis”:
As of 1 November 2015, 7,345 patients with multi-drug resistant tuberculosis enrolled; among them 4,889 patients remained in the program and continue their treatment.
See detailed information
As of 1 October 2015, 6,861 patients with multi-drug resistant tuberculosis enrolled; among them 4,583 patients continue their treatment.
See detailed information
As of 1 September 2015, 6,488 patients with multi-drug resistant tuberculosis enrolled; among them 4,426 patients continue their treatment.
See detailed information
As of 1 July 2015, 5,578 patients were enrolled; among them 3,806 continue their treatment.
See detailed information
As of 1 June 2015, 5,127 patients enrolled; among them 3,573 patients continue their treatment
See detailed information
As of 1 May 2015, 4,758 patients enrolled; among them 3,329 patients continue their treatment
See detailed information
As of 1 March 2015, 4,520 patients enrolled; among them 3,376 patients continue their treatment
See detailed information
As of 1 February 2015, 4,393 patients enrolled; among them 3,409 patients continue their treatment
See detailed information
As of 1 January 2015, 4,067 patients enrolled; among them 3,210 patients continue their treatment
See detailed information